company background image
APEN

Apollo Endosurgery NasdaqGM:APEN Stock Report

Last Price

US$4.67

Market Cap

US$188.0m

7D

19.1%

1Y

-35.1%

Updated

28 May, 2022

Data

Company Financials +
APEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

APEN Stock Overview

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices.

Apollo Endosurgery Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Apollo Endosurgery
Historical stock prices
Current Share PriceUS$4.67
52 Week HighUS$10.39
52 Week LowUS$3.58
Beta2.27
1 Month Change-16.31%
3 Month Change-17.05%
1 Year Change-35.14%
3 Year Change40.66%
5 Year Change-30.30%
Change since IPO-61.60%

Recent News & Updates

Mar 02
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

APENUS Medical EquipmentUS Market
7D19.1%2.9%5.9%
1Y-35.1%-14.9%-10.2%

Return vs Industry: APEN underperformed the US Medical Equipment industry which returned -14.9% over the past year.

Return vs Market: APEN underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is APEN's price volatile compared to industry and market?
APEN volatility
APEN Average Weekly Movement10.3%
Medical Equipment Industry Average Movement10.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: APEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: APEN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005202Chas McKhannhttps://www.apolloendo.com

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.

Apollo Endosurgery Fundamentals Summary

How do Apollo Endosurgery's earnings and revenue compare to its market cap?
APEN fundamental statistics
Market CapUS$187.97m
Earnings (TTM)-US$28.49m
Revenue (TTM)US$65.79m

2.9x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APEN income statement (TTM)
RevenueUS$65.79m
Cost of RevenueUS$28.97m
Gross ProfitUS$36.83m
Other ExpensesUS$65.32m
Earnings-US$28.49m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin55.97%
Net Profit Margin-43.31%
Debt/Equity Ratio96.6%

How did APEN perform over the long term?

See historical performance and comparison

Valuation

Is Apollo Endosurgery undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.42x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: APEN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.

PE vs Market: APEN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APEN is overvalued based on its Price-To-Book Ratio (3.4x) compared to the US Medical Equipment industry average (2.5x).


Future Growth

How is Apollo Endosurgery forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-0.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APEN's revenue (25% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: APEN's revenue (25% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Apollo Endosurgery performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: APEN is currently unprofitable.

Growing Profit Margin: APEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).


Return on Equity

High ROE: APEN has a negative Return on Equity (-51.78%), as it is currently unprofitable.


Financial Health

How is Apollo Endosurgery's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: APEN's short term assets ($108.5M) exceed its short term liabilities ($14.0M).

Long Term Liabilities: APEN's short term assets ($108.5M) exceed its long term liabilities ($56.0M).


Debt to Equity History and Analysis

Debt Level: APEN has more cash than its total debt.

Reducing Debt: APEN's debt to equity ratio has increased from 95.6% to 96.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: APEN has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 4.4% each year.


Dividend

What is Apollo Endosurgery current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate APEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Chas McKhann (52 yo)

1.17yrs

Tenure

US$8,664,627

Compensation

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...


CEO Compensation Analysis

Compensation vs Market: Chas's total compensation ($USD8.66M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Insufficient data to compare Chas's compensation with company performance.


Leadership Team

Experienced Management: APEN's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: APEN's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: APEN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.9%.


Top Shareholders

Company Information

Apollo Endosurgery, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Apollo Endosurgery, Inc.
  • Ticker: APEN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$187.969m
  • Shares outstanding: 40.25m
  • Website: https://www.apolloendo.com

Number of Employees


Location

  • Apollo Endosurgery, Inc.
  • Building 1
  • Suite 300
  • Austin
  • Texas
  • 78746
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.